ATE293458T1 - Antikonvulsive mitteln enthaltende zubereitung zur behandlung von neuropathischen schmerzen - Google Patents

Antikonvulsive mitteln enthaltende zubereitung zur behandlung von neuropathischen schmerzen

Info

Publication number
ATE293458T1
ATE293458T1 AT97938475T AT97938475T ATE293458T1 AT E293458 T1 ATE293458 T1 AT E293458T1 AT 97938475 T AT97938475 T AT 97938475T AT 97938475 T AT97938475 T AT 97938475T AT E293458 T1 ATE293458 T1 AT E293458T1
Authority
AT
Austria
Prior art keywords
treatment
neuropathic pain
preparation containing
anticonvulsive agents
nmda receptor
Prior art date
Application number
AT97938475T
Other languages
English (en)
Inventor
Frank S Caruso
Fredrick L Minn
John W Lyle
Original Assignee
Algos Pharm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Algos Pharm Corp filed Critical Algos Pharm Corp
Application granted granted Critical
Publication of ATE293458T1 publication Critical patent/ATE293458T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT97938475T 1996-08-23 1997-08-21 Antikonvulsive mitteln enthaltende zubereitung zur behandlung von neuropathischen schmerzen ATE293458T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2450896P 1996-08-23 1996-08-23
PCT/US1997/014680 WO1998007447A1 (en) 1996-08-23 1997-08-21 Anticonvulsant containing composition for treating neuropathic pain

Publications (1)

Publication Number Publication Date
ATE293458T1 true ATE293458T1 (de) 2005-05-15

Family

ID=21820954

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97938475T ATE293458T1 (de) 1996-08-23 1997-08-21 Antikonvulsive mitteln enthaltende zubereitung zur behandlung von neuropathischen schmerzen

Country Status (9)

Country Link
US (2) US6187338B1 (de)
EP (1) EP0942752B1 (de)
JP (1) JP2001500121A (de)
AT (1) ATE293458T1 (de)
AU (1) AU4078897A (de)
CA (1) CA2264182A1 (de)
DE (1) DE69733081T2 (de)
ES (1) ES2241055T3 (de)
WO (1) WO1998007447A1 (de)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2241055T3 (es) * 1996-08-23 2005-10-16 Endo Pharmaceuticals Inc Composicion que contiene un anticonvulsionante para tratar el dolor neuropatico.
AU8668598A (en) * 1997-08-20 1999-03-08 University Of Oklahoma, The Gaba analogs to prevent and treat gastrointestinal damage
AU2002301362B8 (en) * 1997-09-08 2006-05-04 Warner-Lambert Company Analgesic compositions comprising anti-epileptic compounds and methods of using same
AU784225B2 (en) * 1997-09-08 2006-02-23 Warner-Lambert Company Analgesic compositions comprising anti-epileptic compounds and methods of using same
DK1011658T3 (da) 1997-09-08 2006-04-03 Warner Lambert Co Analgesiske præparater, der omfatter antiepileptiske forbindelser, og fremgangsmåder til anvendelse af samme
NZ508490A (en) 1998-07-09 2003-08-29 Warner Lambert Co Use of a combination of a GABA analog and caffeine as an analgesic
US6309858B1 (en) 1998-09-29 2001-10-30 Syntex (U.S.A.) Llc T-type calcium channel variants; compositions thereof; and uses
AR022620A1 (es) 1999-02-18 2002-09-04 Ortho Mcneil Pharm Inc Aroil aminoacil pirroles para ser usados en el tratamiento de dolor neuropatico
US6451857B1 (en) 1999-03-10 2002-09-17 Warner-Lambert Company Analgesic compositions comprising anti-epileptic compounds and methods of using same
EP1169060B1 (de) * 1999-04-09 2005-08-31 Euro-Celtique S.A. Natrium kanalblocker zusammensetzungen und deren verwendung
AU5824800A (en) * 1999-06-23 2001-01-31 Warner-Lambert Company Use of fosphenytoin for the treatment of acute neuropathic pain
SK286621B6 (sk) * 1999-08-20 2009-02-05 Ortho-Mcneil Pharmaceutical, Inc. Farmaceutický prostriedok obsahujúci kombináciu tramadolového materiálu a antikonvulzívneho činidla, táto kombinácia a jej použitie na výrobu liečiva
US6573267B2 (en) 2000-06-30 2003-06-03 Ortho-Mcneil Pharmaceutical, Inc. Useful aroyl aminoacyl pyrrole compounds
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
AU2002250256B2 (en) * 2001-03-08 2008-04-03 Emory University pH-dependent NMDA receptor antagonists
ES2632544T3 (es) * 2001-06-07 2017-09-14 Analgesic Neuropharmaceuticals, Llc Tratamiento de dolor neuropático con el antagonista del receptor de N-metil-D-aspartato (NMDA) dextrometorfano
ITMI20011308A1 (it) * 2001-06-21 2002-12-21 Nicox Sa Farmaci per il dolore cronico
DK1423168T3 (da) 2001-09-03 2006-05-15 Newron Pharm Spa Farmaceutisk præparat omfattende gabapentin eller en analog deraf og et alfa-aminoamid og dets analgetiske anvendelse
TWI312285B (en) * 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US20060159743A1 (en) * 2001-10-25 2006-07-20 Depomed, Inc. Methods of treating non-nociceptive pain states with gastric retentive gabapentin
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
AU2003210486B2 (en) * 2002-01-16 2007-06-28 Endo Pharmaceuticals Inc. Pharmaceutical composition and method for treating disorders of the central nervous system
JP2005525848A (ja) * 2002-02-13 2005-09-02 ベス イスラエル ディコネス メディカル センター 血管疾患の治療方法
US20030225002A1 (en) * 2002-02-26 2003-12-04 Livingstone Ian R. Co-therapy for the treatment of migraine comprising anticonvulsant derivatives and anti-migraine agents
US8097585B2 (en) 2002-04-15 2012-01-17 Beth Israel Deaconess Medical Center, Inc. Methods of treating inflammation by administration of heme oxygenase-1 and products of heme degradation
AU2003279236B8 (en) * 2002-06-21 2009-02-19 Beth Israel Deaconess Medical Center, Inc. Pharmaceutical use of nitric oxide, heme oxygenase-1 and products of heme degradation
US8637512B2 (en) * 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
EP1524981B1 (de) * 2002-07-29 2009-03-11 Glaxo Group Limited Zusammensetzung mit verzögerter freisetzung enthaltend lamotrigin
AU2003297639A1 (en) * 2002-12-02 2004-06-23 University Of Florida Treatments for benign tumors, cancers, neoplasias, and/or other inflammatory disorders or diseases
HUP0300929A3 (en) * 2003-04-09 2005-06-28 Richter Gedeon Vegyeszet Analgetic and/or muscle relaxant pharmaceutical composition
WO2005019166A2 (en) * 2003-06-11 2005-03-03 Neuromolecular, Inc. Method of targeting a therapeutic agent
US20040265364A1 (en) * 2003-06-25 2004-12-30 Binnur Ozturk Neuropathy cream
WO2005051325A2 (en) * 2003-11-25 2005-06-09 Sb Pharmco Puerto Rico Inc. Carvedilol compositions methods of treatment and delivery
EP1715843A1 (de) * 2004-01-29 2006-11-02 Neuromolecular Inc. Kombination eines nmda-rezeptor-antagonisten und eines mao-hemmers oder eines gadph-hemmers zur behandlung von erkrankungen im zusammenhang mit dem zentralen nervensystem
EP1727538A2 (de) * 2004-02-13 2006-12-06 Neuromolecular Inc. Kombination aus einem nmda-rezeptor-antagonisten und einem antiepileptikum zur behandlung von epilepsie und anderen störungen des zns
MY147767A (en) 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
AR049646A1 (es) * 2004-06-16 2006-08-23 Janssen Pharmaceutica Nv Derivados de sulfamato y sulfamida utiles para el tratamiento de la epilepsia y trastornos relacionados
US20060002999A1 (en) * 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
US20060034910A1 (en) * 2004-08-09 2006-02-16 Sanjay Patel Pharmaceutical composition for extended release of phenytoin sodium
AU2005277134A1 (en) * 2004-08-24 2006-03-02 Janssen Pharmaceutica N.V. Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents
ES2347581T3 (es) * 2004-09-10 2010-11-02 Newron Pharmaceuticals S.P.A. Uso de (r)-(halobenciloxi)bencilamino-propanamidas como moduladores selectivos del canal de sodio y/o calcio.
EP1827385B1 (de) 2004-11-23 2013-03-27 Adamas Pharmaceuticals, Inc. Pharmazeutische zusammensetzung enthaltend memantin in verzögerter freisetzungs-form zur behandlung von dementia
US7619007B2 (en) * 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
US8389578B2 (en) 2004-11-24 2013-03-05 Adamas Pharmaceuticals, Inc Composition and method for treating neurological disease
KR101406456B1 (ko) * 2005-04-06 2014-06-20 아다마스 파마슈티칼스, 인코포레이티드 Ｃｎｓ 장애의 치료를 위한 방법 및 조성물
WO2006119295A2 (en) * 2005-05-02 2006-11-09 Combinatorx, Incorporated Compositions and methods for the treatment of neurodegenerative diseases
US20090143450A1 (en) * 2005-05-06 2009-06-04 University Of Maryland, Baltimore Method for treating central pain syndrom or for inducing centrally generated pain in an animal model
EA200702558A1 (ru) 2005-05-20 2008-06-30 Янссен Фармацевтика Н. В. Способ получения производных сульфамида
EP1900363A4 (de) 2005-06-27 2010-01-13 Ono Pharmaceutical Co Therapeutisches mittel gegen schmerzen
US8691867B2 (en) 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US8497298B2 (en) 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US20070155827A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
US8492431B2 (en) 2005-12-19 2013-07-23 Janssen Pharmaceutica, N.V. Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
US20070155823A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents
US8716231B2 (en) 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
BRPI0620239B8 (pt) * 2005-12-22 2021-05-25 Newron Pharm Spa derivados de 2-feniletilamino.
US20090176882A1 (en) 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
US20070191474A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of migraine
US20070191449A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Depression
US20070191461A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives for the treatment of migraine
US20070191452A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives for the treatment of pain
WO2007120485A2 (en) * 2006-03-30 2007-10-25 Cinergen, Llc Methods of treating pain with alkylxanthines and antiepileptics and compositions for use therefor
AU2007253814A1 (en) 2006-05-19 2007-11-29 Janssen Pharmaceutica N.V. Co-therapy for the treatment of epilepsy
US20120083508A1 (en) 2006-12-22 2012-04-05 Allergan, Inc. Alpha-2b receptor agonist and anticonvulsant compositions for treating chronic pain
US20100016355A1 (en) * 2006-12-22 2010-01-21 Gil Daniel W Alpha-2b adrenergic receptor agonist and serotonin-norepinephrine reuptake inhibitor compositions for treating chronic pain
US8420680B2 (en) 2007-06-29 2013-04-16 Emory University NMDA receptor antagonists for neuroprotection
CA2701838A1 (en) * 2007-10-09 2009-04-16 Merck Patent Gmbh Pharmaceutical compositions containing benfotiamine and one or more pharmaceutically active agents for the treatment of pain conditions of neuropathic origin
US20090247616A1 (en) * 2008-03-26 2009-10-01 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of anxiety
US20090247617A1 (en) * 2008-03-26 2009-10-01 Abdel-Magid Ahmed F Process for the preparation of benzo-fused heteroaryl sulfamates
US20090247644A1 (en) * 2008-03-28 2009-10-01 Forest Laboratories Holdings Limited Memantine formulations
EA018567B1 (ru) 2008-06-23 2013-08-30 Янссен Фармацевтика Нв Кристаллическая форма (2s)-(-)-n-(6-хлор-2,3-дигидробензо[1,4]диоксин-2-илметил)сульфамида
US8815939B2 (en) 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
CA2738468A1 (en) 2008-09-27 2010-04-01 Taraxos Inc. Topical formulations for treatment of neuropathy
CA2782556C (en) 2009-12-02 2018-03-27 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use
WO2011127235A1 (en) 2010-04-07 2011-10-13 Eisai Inc. Combination therapy for the treatment of dementia
FR2998892B1 (fr) 2012-12-04 2015-01-02 Pf Medicament Derives d'aminocyclobutane, leur procede de preparation et leur utilisation a titre de medicaments
WO2014204933A1 (en) 2013-06-17 2014-12-24 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use
BR112016014611A8 (pt) 2013-12-24 2023-05-09 Univ Virginia Commonwealth Usos de sulfatos de colesterol oxigenados (ocs)
US11147799B2 (en) 2016-12-06 2021-10-19 Jan Marius Keppel Hesselink Topical pharmaceutical composition containing phenytoin and a (co-) analgesic for the treatment of chronic pain
US11285099B2 (en) 2016-12-06 2022-03-29 Topical Innovations B.V. Topical phenytoin for use in the treatment of peripheral neuropathic pain
KR20210002472A (ko) * 2018-04-16 2021-01-08 바이오젠 엠에이 인코포레이티드 신경병증성 통증을 치료하는 방법
CN113557018A (zh) * 2018-09-14 2021-10-26 国立大学法人富山大学 急性带状疱疹疼痛的治疗剂
WO2022113069A1 (en) 2020-11-24 2022-06-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. E protein channel blockers and orf3 inhibitors as anti-covid-19 agents
WO2021220284A1 (en) 2020-05-01 2021-11-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. E protein channel blockers and orf3 inhibitors as anti-covid-19 agents
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4694010A (en) * 1985-08-16 1987-09-15 New York University Anticonvulsant compositions and method
US4906638A (en) * 1987-12-22 1990-03-06 Nova Pharmaceutical Corporation Dextromethorphan potentiator for anticonvulsant composition and method
AU2929489A (en) * 1987-12-22 1989-07-19 John W. FERKANY Dextrorphan potentiator for anticonvulsant composition and method
US5075114A (en) * 1990-05-23 1991-12-24 Mcneil-Ppc, Inc. Taste masking and sustained release coatings for pharmaceuticals
US5234929A (en) * 1992-07-20 1993-08-10 William Chelen Method of treating motion sickness with anticonvulsants and antitussive agents
CA2115792C (en) * 1993-03-05 2005-11-01 David J. Mayer Method for the treatment of pain
ES2241055T3 (es) * 1996-08-23 2005-10-16 Endo Pharmaceuticals Inc Composicion que contiene un anticonvulsionante para tratar el dolor neuropatico.
US6057373A (en) * 1997-05-22 2000-05-02 Synchroneuron, Llc Methods of treating tardive dyskinesia and other movement disorders using NMDA receptor antagonists

Also Published As

Publication number Publication date
CA2264182A1 (en) 1998-02-26
US6187338B1 (en) 2001-02-13
JP2001500121A (ja) 2001-01-09
US6406716B2 (en) 2002-06-18
WO1998007447A1 (en) 1998-02-26
AU4078897A (en) 1998-03-06
DE69733081T2 (de) 2006-05-11
US20010008889A1 (en) 2001-07-19
EP0942752B1 (de) 2005-04-20
EP0942752A1 (de) 1999-09-22
ES2241055T3 (es) 2005-10-16
DE69733081D1 (de) 2005-05-25

Similar Documents

Publication Publication Date Title
ATE293458T1 (de) Antikonvulsive mitteln enthaltende zubereitung zur behandlung von neuropathischen schmerzen
ATE301994T1 (de) Verfahren zur erleichterung von schmerzen durch eine kombination von tramadol und einen nmda- antagonist
DE69727922D1 (de) Schnell zerfallende orale dosierungsform
ATE214277T1 (de) Schmerzlindernde arzneistoffzusammensetzung
DE69634609D1 (de) Analgesiche synergie durch gleichzeitige verabreichung von subanalgesichen doseneines mu-opioidanagonisten und eines kappa - 2- opioidanagonisten
HUP0004532A2 (en) Synergistic analgesic combination of opioid analgesic and cyclooxygenase-2 inhibitor
HU9603228D0 (en) Pharmaceutical compositions comprising an opiate antagonist and calcium salts, their use for the treatment of endorphin-mediated pathologies
BG103552A (en) Therapeutical forms
ATE288444T1 (de) Dipeptide, die die ausschüttung von wachstumshormonen stimulieren
NO20053105D0 (no) Oral, analgesisk doseringsform med forlenget frigivelse for administrering ±n gang pr. dag.
PL318172A1 (en) Novel analgesic pharmaceutic preparation
BR9508671A (pt) Método de alívio da dor e composição terapêutica
DE69711078D1 (de) Topische verwendung von kappa-opioidrezeptoragonisten zur behandlung von augenschmerz
FI972434A0 (fi) Lamotrigiiniä sisältävä farmaseuttinen koostumus
ATE221391T1 (de) Konjugat enthaltend dtpa und albumin zur individuellen dosierung von arzneimitteln
PL312198A1 (en) Application of procaine in obtaining a pharmaceutical preparation of analgesic activity with minimum motorial blocking effect
ATE280575T1 (de) Transdermales therapeutisches system zur anwendung von candesartan
EP1011672A4 (de) Verbindungen mit analgetischem effekt und zusammenstellungen die diese enthalten

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties